FI970198A0 - Neuraliserande humana monoklonala antikroppar mot humant immunbristvirus - Google Patents

Neuraliserande humana monoklonala antikroppar mot humant immunbristvirus

Info

Publication number
FI970198A0
FI970198A0 FI970198A FI970198A FI970198A0 FI 970198 A0 FI970198 A0 FI 970198A0 FI 970198 A FI970198 A FI 970198A FI 970198 A FI970198 A FI 970198A FI 970198 A0 FI970198 A0 FI 970198A0
Authority
FI
Finland
Prior art keywords
neuralizing
monoclonal antibodies
antibodies against
immunodeficiency virus
human
Prior art date
Application number
FI970198A
Other languages
English (en)
Finnish (fi)
Other versions
FI970198A (sv
Inventor
Dennis R Burton
Carlos F Barbas
Richard A Lerner
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of FI970198A0 publication Critical patent/FI970198A0/sv
Publication of FI970198A publication Critical patent/FI970198A/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI970198A 1994-07-18 1997-01-17 Neuraliserande humana monoklonala antikroppar mot humant immunbristvirus FI970198A (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/276,852 US5652138A (en) 1992-09-30 1994-07-18 Human neutralizing monoclonal antibodies to human immunodeficiency virus
PCT/US1995/008743 WO1996002273A1 (en) 1994-07-18 1995-07-11 Human neutralizing monoclonal antibodies to human immunodeficiency virus

Publications (2)

Publication Number Publication Date
FI970198A0 true FI970198A0 (sv) 1997-01-17
FI970198A FI970198A (sv) 1997-03-17

Family

ID=23058336

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970198A FI970198A (sv) 1994-07-18 1997-01-17 Neuraliserande humana monoklonala antikroppar mot humant immunbristvirus

Country Status (8)

Country Link
US (2) US5652138A (sv)
EP (1) EP0777497A4 (sv)
JP (1) JPH10505229A (sv)
AU (1) AU706601B2 (sv)
CA (1) CA2195454A1 (sv)
FI (1) FI970198A (sv)
NO (1) NO970221L (sv)
WO (1) WO1996002273A1 (sv)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030187247A1 (en) * 1992-09-30 2003-10-02 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
US5652138A (en) * 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
US20060078561A1 (en) * 1994-01-31 2006-04-13 The Trustees Of Boston University Polyclonal antibody libraries
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
US6193982B1 (en) 1995-04-27 2001-02-27 The United States Of America As Represented By The Department Of Health & Human Services Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120
US7048935B2 (en) 1995-04-27 2006-05-23 The United States Of America As Represented By The Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6428790B1 (en) 1995-04-27 2002-08-06 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6780847B2 (en) 1995-04-27 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
US5843882A (en) 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
US6987096B1 (en) 1995-04-27 2006-01-17 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
US6265215B1 (en) 1996-09-13 2001-07-24 Ludwig Institute For Cancer Research Isolated peptides which complex with HLA-Cw16 and uses thereof
IL140701A0 (en) 1998-07-13 2002-02-10 Univ Texas Cancer treatment methods using antibodies to aminophospholipids
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6482928B1 (en) * 1999-04-13 2002-11-19 Aventis Pasteur Limited And University Of Toronto Fab′-epitope complex from HIV-1 cross-neutralizing monoclonal antibody 2F5
US20040063605A1 (en) * 2000-08-02 2004-04-01 Jesper Eugen-Olsen Composition and method for the treatment or prevention of hiv infection
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
CA2441287C (en) 2001-03-22 2014-06-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
US20020146753A1 (en) * 2001-04-06 2002-10-10 Henrik Ditzel Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
WO2002090510A2 (en) * 2001-05-08 2002-11-14 Emory University Regulating immine responses using dendritic cells
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
EP1450857B1 (en) * 2001-10-16 2010-09-15 The Government of the United States of America, represented by The Secretary, Department of Health and Human Services Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes
CN1856504B (zh) 2002-02-06 2010-12-29 史戴西思技术有限公司 抗梗塞分子
EP1572937B1 (en) 2002-04-09 2012-02-08 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof
WO2003092630A2 (en) * 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
WO2003095492A1 (en) * 2002-05-06 2003-11-20 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
US7429360B2 (en) * 2002-05-28 2008-09-30 Autogenomics, Inc. Level-controlled pipette for automated analytic devices
AU2003243151A1 (en) * 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
JP4824312B2 (ja) * 2002-11-26 2011-11-30 ユニバーシティ オブ ユタ リサーチ ファンデーション 微小孔物質、被分析物の局在化及び定量の方法、並びに被分析物の局在化及び定量用物品
US7597936B2 (en) * 2002-11-26 2009-10-06 University Of Utah Research Foundation Method of producing a pigmented composite microporous material
WO2004053100A2 (en) * 2002-12-11 2004-06-24 The Scripps Research Institute Immunogenic mutant human immunodeficiency virus gp120 polypeptides, and methods of using same
US20060231107A1 (en) 2003-03-07 2006-10-19 Glickman Randolph D Antibody-targeted photodynamic therapy
JP2007515394A (ja) * 2003-05-06 2007-06-14 ザ スクリプス リサーチ インスティチュート ドメイン交換結合分子、その使用方法および製造方法
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
JP2007518422A (ja) 2004-01-21 2007-07-12 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション 変異体ナトリウムチャンネルＮａν１．７およびそれに関連する方法
AU2005211790B2 (en) * 2004-02-09 2010-03-11 Northeastern University Monoclonal antibody based biomarker discovery and development platform
WO2006044410A2 (en) * 2004-10-14 2006-04-27 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services A32 monoclonal antibody fusion proteins for use as hiv inhibitors and vaccines
AU2005302416A1 (en) * 2004-10-29 2006-05-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies
ES2328507T3 (es) 2004-12-29 2009-11-13 Seattle Biomedical Research Institute Proteinas de envoltura del vih heterooligomericas.
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
CN101166976B (zh) * 2005-01-13 2013-06-12 诺华疫苗和诊断公司 利用朊病毒特异性肽试剂的elisa试验
WO2007084568A2 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
EP1998792B1 (en) * 2006-03-01 2015-02-18 The University of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
US8470965B2 (en) * 2006-03-01 2013-06-25 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
US7492312B2 (en) * 2006-11-14 2009-02-17 Fam Adly T Multiplicative mismatched filters for optimum range sidelobe suppression in barker code reception
JP2010514839A (ja) * 2007-01-03 2010-05-06 バーナム インスティテュート フォー メディカル リサーチ クロット結合化合物に関連する方法および組成物
EP2115173B1 (en) 2007-01-08 2011-09-21 Government of the USA, as Represented by the Secretary, Department of Health and Human Services Slco1b3 genotype
US7776331B1 (en) * 2007-01-16 2010-08-17 Abbott Laboratories Methods of treating plaque psoriasis
CA2681752A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
EP2478766A3 (en) 2007-05-09 2012-08-15 Burnham Institute for Medical Research Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens
EP2164957B1 (en) 2007-05-23 2017-07-12 The UAB Research Foundation Detoxified pneumococcal neuraminidase and uses thereof
US20100239596A1 (en) * 2007-08-22 2010-09-23 University Of Southern California Grp78 and tumor angiogenesis
EP2195340A4 (en) 2007-08-28 2011-05-11 Uab Research Foundation SYNTHETIC APOLIPOPROTEIN E-IMITATING POLYPEPTIDES AND METHOD OF USE
CA2704729C (en) 2007-08-28 2020-06-23 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
EP2268664B1 (en) * 2007-12-03 2017-05-24 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Doc1 compositions and methods for treating cancer
RU2497545C2 (ru) 2008-03-18 2013-11-10 Эбботт Лэборетриз Способ лечения псориаза (варианты)
AU2009243060A1 (en) * 2008-04-30 2009-11-05 Novartis Ag. Assay for pathogenic conformers
WO2010019120A1 (en) 2008-08-15 2010-02-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health S0x9, prostaglandin d2 and retinoic acid for treating pigmentary conditions and melanoma
CA2736799A1 (en) 2008-08-25 2010-03-11 Burnham Institute For Medical Research Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
NZ592644A (en) * 2008-11-28 2013-09-27 Abbott Lab Stable antibody compositions and methods for stabilizing same
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
WO2011020107A2 (en) 2009-08-14 2011-02-17 Georgetown University Compositions and methods for detection and treatment of breast cancer
MX2012003138A (es) 2009-09-14 2012-07-04 Abbott Lab Y Abbott Gmbh & Co Kg Metodos para tratar la psoriasis.
CA2775747A1 (en) 2009-10-07 2011-04-14 Sanford Burnham Medical Research Institute Methods and compositions related to clot-binding lipid compounds
CA2784145A1 (en) 2009-12-18 2011-06-23 Sanford-Burnham Medical Research Institute Methods and compositions related to clot-binding compounds
WO2011088391A2 (en) 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
EP2569335B1 (en) 2010-05-14 2018-08-22 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
US9051619B2 (en) 2011-03-25 2015-06-09 Florida Agricultural and Mechanical University (FAMU) Methods and compositions for prostate cancer metastasis
SI2691530T1 (en) 2011-06-10 2018-08-31 Oregon Health & Science University CMV glycoproteins and recombinant vectors
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US20150175678A1 (en) * 2012-06-15 2015-06-25 Beth Israel Deaconess Medical Center, Inc. IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US20140094383A1 (en) 2012-10-02 2014-04-03 Ohio State Innovation Foundation Tethered Lipoplex nanoparticle Biochips And Methods Of Use
WO2014201118A2 (en) 2013-06-11 2014-12-18 Sanford-Burnham Medical Research Institute Compositions and methods for targeted endometriosis treatment
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US9481729B2 (en) 2013-09-11 2016-11-01 The University Of Hong Kong Anti-HER2 and anti-IGF-IR BI-specific antibodies and uses thereof
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9840555B2 (en) 2013-11-04 2017-12-12 Li-Te Chin Method for producing human monoclonal antibodies that binds to at least one part of HMGB1
US10653747B2 (en) 2014-07-31 2020-05-19 Uab Research Foundation ApoE mimetic peptides and higher potency to clear plasma cholesterol
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CN108779168A (zh) 2015-12-05 2018-11-09 沃迪奥斯大学医院中心 Hiv结合剂
US20190309070A1 (en) 2016-10-05 2019-10-10 University Of Central Florida Research Foundation, Inc. Methods and compositions related to nk cell and anti-pdl1 cancer therapies
BR112019020386A2 (pt) 2017-03-28 2020-06-09 Mayo Found Medical Education & Res vacinas de peptídeos de pd-1 humana e usos das mesmas
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
WO2019118686A1 (en) 2017-12-13 2019-06-20 North Carolina State University Compositions comprising chemotherapeutic agents and checkpoint inhibitors and methods of use
CA3104664A1 (en) 2018-06-29 2020-01-02 North Carolina State University In situ sprayed bioresponsive immunotherapeutic gel for post-surgical treatment
WO2020012435A1 (en) 2018-07-13 2020-01-16 Lausanne University Hospital Hiv binding agents
EP4400840A2 (en) 2018-12-27 2024-07-17 University Of Utah Research Foundation Compositions and methods useful in detecting and treating multiple sclerosis and other demyelinating diseases
MX2021009020A (es) * 2019-01-28 2021-09-28 Xyphos Biosciences Inc Ligandos nkg2d no naturales modificados que entregan selectivamente moleculas heterologas unidas a receptores nkg2d no naturales en celulas car.
BR112021025795A2 (pt) 2019-06-21 2022-02-01 H Lee Moffitt Cancer Center And Res Institute Inc A Florida Non Profit Corporation Terapia de combinação com bloqueio da semaforina-4d (sema4d) e terapia com dc1
US20220267416A1 (en) 2019-07-15 2022-08-25 Lausanne University Hospital Hiv binding agents
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University METHODS AND COMPOSITIONS FOR IDENTIFYING NEOANTIGENS FOR USE IN THE TREATMENT AND PREVENTION OF CANCER
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
EP4146327A1 (en) 2020-05-08 2023-03-15 Novocure GmbH Compositions and methods of applying alternating electric fields to pluripotent stem cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5652138A (en) * 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus

Also Published As

Publication number Publication date
CA2195454A1 (en) 1996-02-01
NO970221L (no) 1997-03-18
AU706601B2 (en) 1999-06-17
AU2970095A (en) 1996-02-16
EP0777497A4 (en) 1998-01-07
EP0777497A1 (en) 1997-06-11
US5804440A (en) 1998-09-08
FI970198A (sv) 1997-03-17
WO1996002273A1 (en) 1996-02-01
JPH10505229A (ja) 1998-05-26
NO970221D0 (no) 1997-01-17
US5652138A (en) 1997-07-29

Similar Documents

Publication Publication Date Title
FI970198A0 (sv) Neuraliserande humana monoklonala antikroppar mot humant immunbristvirus
DK1516629T3 (da) Humaniseret anti-CD-11a antibodies
NO955167D0 (no) Monoklonalt anti-
NO991449D0 (no) Antistoff mot human parathormon-relaterte peptider
NO20013147L (no) Humane monoklonale antistoff mot CTLA-4
NO985464D0 (no) Konsentrert antistoffpreparat
FI962377A0 (sv) Humaniserade antikroppar och användning av dessa
DK145493D0 (da) Antistof
EE05627B1 (et) CTLA-4 vastased inimese monoklonaalsed antikehad
DE69738312D1 (de) Hepatitis b monoklonale antikörper
DE69614331D1 (de) Signalangepasstes Filter
AU7203194A (en) Bispecific human monoclonal antibodies specific for human immunodeficiency virus
NO920523L (no) Ige-reseptor-antistoff
NO981272D0 (no) Humanisert anti-human-Fas-antistoff
DE59608307D1 (de) Nutenstanzmaschine
DE69322847D1 (de) Monoklonaler Antikörper gegen menschliches Ceruloplasmin
ATA98795A (de) Anti-plasma-antikörper-präparation
NO890116L (no) Monoklonale antistoffer.
DK413389D0 (da) Monoklonale antistoffer
AU3432389A (en) Human monoclonal antibodies against rabies virus
ITRM920223A0 (it) Anticorpi monoclonali anti-idiopici diretti contro anticorpi anti-tnf.
DE69427850D1 (de) Monoklonaler antikörper gegen mucoglykoprotein
FI925638A0 (fi) Monoklonal antikropp 88bv59 riktad mot en i samband med tumoerer foerekommande antigen
BR9709080A (pt) Anticorpo monoclonal anti-MP52 humano
KR970007784U (ko) 미꾸라지 통발